ALK Abello

Historical price data

ALK Abello is a century-old Danish specialty pharmaceutical company focused on allergy solutions, operating as a global leader in allergy immunotherapy with a comprehensive pipeline spanning respiratory allergies, food allergies, anaphylaxis, and adjacent therapy areas. The company has pioneered breakthrough technologies including sublingual immunotherapy tablets and is developing next-generation treatments like EURneffy, a needle-free anaphylaxis treatment. With their 'Allergy+' strategy for 2024-2028, ALK aims to leverage cutting-edge AI and digital innovation to accelerate drug discovery and help more people with more solutions more efficiently.

ALK specializes in allergy immunotherapy (AIT) with pioneering sublingual tablet technology, comprehensive biomarker discovery platforms, and AI-powered drug discovery capabilities focused on Type 2 immune mechanisms and allergic disease modification.

Total raised: $500M

ALK operates as a established leader in allergy immunotherapy with over 100 years of experience, competing against both traditional pharmaceutical companies and emerging biotech firms in the allergy space. The company differentiates through its pioneering sublingual tablet technology, comprehensive allergy expertise, and innovative delivery methods like needle-free devices.